

Country	Year	Value
Algeria	1990	1.00
Algeria	1991	1.00
Algeria	1992	1.00
Algeria	1993	1.00
Algeria	1994	1.00
Algeria	1995	1.00
Algeria	1996	1.00
Algeria	1997	1.00
Algeria	1998	1.00
Algeria	1999	1.00
Algeria	2000	1.00
Algeria	2001	1.00
Algeria	2002	1.00
Algeria	2003	1.00
Algeria	2004	1.00
Algeria	2005	1.00
Algeria	2006	1.00
Algeria	2007	1.00
Algeria	2008	1.00
Algeria	2009	1.00
Algeria	2010	1.00
Algeria	2011	1.00
Algeria	2012	1.00
Algeria	2013	1.00
Algeria	2014	1.00
Algeria	2015	1.00
Algeria	2016	1.00
Algeria	2017	1.00
Algeria	2018	1.00
Algeria	2019	1.00
Algeria	2020	1.00
Algeria	2021	1.00
Algeria	2022	1.00
Algeria	2023	1.00
Algeria	2024	1.00
Algeria	2025	1.00
Algeria	2026	1.00
Algeria	2027	1.00
Algeria	2028	1.00
Algeria	2029	1.00
Algeria	2030	1.00
Algeria	2031	1.00
Algeria	2032	1.00
Algeria	2033	1.00
Algeria	2034	1.00
Algeria	2035	1.00
Algeria	2036	1.00
Algeria	2037	1.00
Algeria	2038	1.00
Algeria	2039	1.00
Algeria	2040	1.00
Algeria	2041	1.00
Algeria	2042	1.00
Algeria	2043	1.00
Algeria	2044	1.00
Algeria	2045	1.00
Algeria	2046	1.00
Algeria	2047	1.00
Algeria	2048	1.00
Algeria	2049	1.00
Algeria	2050	1.00
Algeria	2051	1.00
Algeria	2052	1.00
Algeria	2053	1.00
Algeria	2054	1.00
Algeria	2055	1.00
Algeria	2056	1.00
Algeria	2057	1.00
Algeria	2058	1.00
Algeria	2059	1.00
Algeria	2060	1.00
Algeria	2061	1.00
Algeria	2062	1.00
Algeria	2063	1.00
Algeria	2064	1.00
Algeria	2065	1.00
Algeria	2066	1.00
Algeria	2067	1.00
Algeria	2068	1.00
Algeria	2069	1.00
Algeria	2070	1.00
Algeria	2071	1.00
Algeria	2072	1.00
Algeria	2073	1.00
Algeria	2074	1.00
Algeria	2075	1.00
Algeria	2076	1.00
Algeria	2077	1.00
Algeria	2078	1.00
Algeria	2079	1.00
Algeria	2080	1.00
Algeria	2081	1.00
Algeria	2082	1.00
Algeria	2083	1.00
Algeria	2084	1.00
Algeria	2085	1.00
Algeria	2086	1.00
Algeria	2087	1.00
Algeria	2088	1.00
Algeria	2089	1.00
Algeria	2090	1.00
Algeria	2091	1.00
Algeria	2092	1.00
Algeria	2093	1.00
Algeria	2094	1.00
Algeria	2095	1.00
Algeria	2096	1.00
Algeria	2097	1.00
Algeria	2098	1.00
Algeria	2099	1.00
Algeria	2100	1.00
Algeria	2101	1.00
Algeria	2102	

1. Pharmaceutical composition containing, as active ingredient, one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant substance(s) possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support.
2. Pharmaceutical composition according to claim 1, containing, as active ingredient, a NO synthase inhibitory substance and a metabolic antioxidant substance.
3. Pharmaceutical composition according to one of claims 1 to 2, characterized in that the NO synthase inhibitory substance and the metabolic antioxidant substance are in separated form.
4. Pharmaceutical composition according to one of claims 1 to 3, in which the metabolic antioxidant is dithiothreitol, pyritinol, lipoic acid or its derivatives, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or the peptides comprising at least two cysteine residues.
5. Pharmaceutical composition according to one of claims 1 to 2, characterized in that the NO synthase inhibitory substance and the metabolic antioxidant substance are in the form of a salt.
6. Pharmaceutical composition according to claim 5, characterized in that the salt is formed from a derivative of the NO synthase inhibitory substance containing at least one basic group and a derivative of the metabolic antioxidant substance containing at least one acid group.
7. Pharmaceutical composition according to one of claims 5 to 6, in which the metabolic antioxidant is lipoic acid or its derivatives, the dimeric disulphide derivatives of penicillamine or N-acetylcysteine, or the peptides containing at least two cysteine residues.
8. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is a compound of amino acid type or a compound of the guanidine, isothioureia, nitro- or cyano-aryl, amino-pyridine or amino-pyrimidine, amidine, indazole or imidazole families.

Figure 1 consists of 15 small graphs arranged vertically, each showing the time course of a different physiological variable during a 100 km triathlon. The x-axis for all graphs represents time in hours, ranging from 0 to 10. The y-axis represents the value of the variable. The variables are: (a) Time, (b) Distance, (c) Heart rate, (d) HRmax, (e) HRmin, (f) HRmean, (g) HRSD, (h) HRmax/HRmin, (i) HRmax/HRmean, (j) HRmax/HRSD, (k) HRmax/HRSD, (l) HRmax/HRSD, (m) HRmax/HRSD, (n) HRmax/HRSD, (o) HRmax/HRSD. Each graph shows a different pattern of change over time, reflecting the physiological demands of the triathlon.

9. Pharmaceutical composition according to claim 8 in which the NO synthase inhibitor of amino-acid type is L-arginine, ornithine or lysine derivatives.
10. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is chosen from L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl) imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophenecarboximidamide, S-ethylisothiurea, S-methyl-L-thiocitrulline or S-ethyl-L-thiocitrulline.
11. Pharmaceutical composition according to one of the preceding claims, in which the metabolic antioxidant is lipoic acid in racemic or enantiomeric form.
12. Pharmaceutical composition according to one of the preceding claims, in which the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.
13. Product containing one or many NO synthase inhibitory substance(s) and one or many metabolic antioxidant substance(s) possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, as combination product in separated form, for simultaneous or sequential use in the treatment of pathologies in which nitrogen monoxide and the redox status of thiol groups are involved.
14. Product according to claim 13 for the treatment of pathologies such as cardiovascular and cerebrovascular disorders, septic shock, radioactive irradiation, solar radiation, organ transplants, disorders of the central or peripheral nervous system and more particularly Parkinson's disease, proliferative and inflammatory diseases, autoimmune and viral diseases, diabetes and its complications, autosomal genetic diseases and all the pathologies characterized by a production or a dysfunction of nitrogen monoxide and/or involving the redox status of thiol groups.
15. Product according to claim 14, for the treatment of cerebrovascular and cardiovascular disorders such as migraine, arterial hypertension, cardiac or cerebral infarctions of ischemic or haemorrhagic origin, ischemias and thromboses.
16. Product according to claim 14, for the treatment of disorders of the central or peripheral nervous system such as neurodegenerative diseases, and more particularly Parkinson's disease, pain, cerebral or bone marrow traumas, addiction to opiates,



~~According to one of claims 13  
and/or inductive NO synthase~~

Add  $a^3$

Figure 1 is a schematic representation of the experimental design. It shows a flow from 'Study 1' to 'Study 2'. Study 1 involves 'Pretest' and 'Main Study'. Study 2 involves 'Pretest' and 'Main Study'. The 'Main Study' in both studies involves 'Participants' and 'Conditions'. The 'Conditions' are 'Control' and 'Intervention'. The 'Intervention' is 'Cognitive Behavioral Therapy (CBT)'. The 'Control' is 'Waitlist Control'. The 'Intervention' is 'Cognitive Behavioral Therapy (CBT)'. The 'Control' is 'Waitlist Control'. The 'Intervention' is 'Cognitive Behavioral Therapy (CBT)'. The 'Control' is 'Waitlist Control'.